

***Fiscal Year 2019 Neurofibromatosis Research Program (NFRP)***  
***Reference Table of Award Mechanisms and Submission Requirements***

<b>Award Mechanism</b>	<b>Eligibility</b>	<b>Key Mechanism Elements</b>	<b>Funding</b>	<b>Submission Deadline</b>
<b>Clinical Trial Award</b> <b>Go to:</b> <ul style="list-style-type: none"> <li>Program Announcement</li> <li>General Application Instructions</li> </ul> <b>Grants.gov Funding Opportunity Number:</b> W81XWH-19-NFRP-CTA	Must be <i>at or above</i> the level of Assistant Professor (or equivalent).	<ul style="list-style-type: none"> <li>Supports research with the potential to have a major impact on the treatment or management of neurofibromatosis (NF).</li> <li>Funds Phase 0, I, or II clinical trials relevant to NF and/or schwannomatosis. Combinations of phases are permitted.</li> <li><b><i>Must support a clinical trial and may not be used for preclinical research studies.</i></b></li> </ul>	<ul style="list-style-type: none"> <li>The maximum period of performance is <b>4</b> years.</li> <li>The maximum allowable funding for the entire period of performance is <b>\$800,000</b> in direct costs (<b>\$1,000,000</b> in direct costs if requesting the Qualified Collaborator Option).</li> <li>Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.</li> </ul>	<b>Pre-Application (Letter of Intent):</b> May 23, 2019 5:00 p.m. Eastern time (ET)  <b>Application:</b> June 6, 2019 11:59 p.m. ET
<b>Exploration – Hypothesis Development Award</b> <b>Go to:</b> <ul style="list-style-type: none"> <li>Program Announcement</li> <li>General Application Instructions</li> </ul> <b>Grants.gov Funding Opportunity Number:</b> W81XWH-19-NFRP-EHDA	Investigators at all academic levels (or equivalent).	<ul style="list-style-type: none"> <li>Supports the initial exploration of innovative, high-risk, high-gain concepts and potentially groundbreaking concepts in NF research.</li> <li><b><i>Preliminary and/or published data encouraged but not required.</i></b></li> <li>Projects involving human subjects or human anatomical substances must be exempt under 32 CFR 219.104(d) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110.</li> <li>Clinical trials not allowed.</li> </ul>	<ul style="list-style-type: none"> <li>The maximum period of performance is <b>2</b> years.</li> <li>The maximum allowable funding for the entire period of performance is <b>\$100,000</b> in direct costs.</li> <li>Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.</li> </ul>	<b>Pre-Application (Letter of Intent):</b> May 23, 2019 5:00 p.m. ET  <b>Application:</b> June 6, 2019 11:59 p.m. ET

***Fiscal Year 2019 Neurofibromatosis Research Program (NFRP)***  
***Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Investigator-Initiated Research Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p>W81XWH-19-NFRP-IIRA</p>	<p>Must be an independent investigator <i>at or above</i> the level of Assistant Professor (or equivalent) and must plan to commit at least a 10% level of effort for each budget period for the entirety of the award.</p>	<ul style="list-style-type: none"> <li>• Supports highly rigorous, high-impact research with the potential to make an important contribution to NF research and/or patient care.</li> <li>• <b><i>Preliminary and/or published data required.</i></b></li> <li>• <b>Optional Features:</b> Applications meeting criteria identified in the announcement may apply for a higher level of funding for the following options: Qualified Collaborator and/or NF Open Science Initiative (NF-OSI).</li> <li>• Clinical trials not allowed.</li> </ul>	<ul style="list-style-type: none"> <li>• The maximum period of performance is <b>3</b> years.</li> <li>• The maximum allowable funding for the entire period of performance is <b>\$525,000</b> in direct costs.</li> <li>• The maximum allowable funding for applications including either the Optional Qualified Collaborator <i>or</i> the NF-OSI Option is <b>\$575,000</b> in direct costs.</li> <li>• The maximum allowable funding for applications including <i>both</i> the Optional Qualified Collaborator Option and the NF-OSI Option is <b>\$625,000</b> in direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b>  May 23, 2019  5:00 p.m. ET</p> <p><b>Application:</b>  June 6, 2019  11:59 p.m. ET</p>

***Fiscal Year 2019 Neurofibromatosis Research Program (NFRP)***  
***Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>New Investigator Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> W81XWH-19-NFRP-NIA</p>	<p>Must be either:</p> <ul style="list-style-type: none"> <li>• An independent investigator <i>at or below</i> the level of Assistant Professor (or equivalent) and must plan to commit at least 30% of his/her effort toward the proposed research project; <i>or</i></li> <li>• An established independent investigator in an area other than NF <i>at or above</i> the level of Assistant Professor seeking to transition into a career in NF research and must plan to commit at least 10% of his/her effort toward the proposed research project.</li> </ul> <p>To be eligible, applicants may not have received more than \$300,000 in direct costs for NF research as a Principal Investigator of one or more Federally funded, non-mentored peer reviewed grants.</p>	<ul style="list-style-type: none"> <li>• Supports the continued development of promising independent investigators and/or the transition of established investigators from other research fields into a career in NF research.</li> <li>• Prior experience in NF research is not required.</li> <li>• <i>Preliminary and/or published data relevant to NF and the proposed research project is required.</i></li> <li>• Clinical trials not allowed.</li> </ul>	<ul style="list-style-type: none"> <li>• The maximum period of performance is <b>3</b> years.</li> <li>• The maximum allowable funding for the entire period of performance is <b>\$450,000</b> in direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> May 23, 2019 5:00 p.m. ET</p> <p><b>Application:</b> June 6, 2019 11:59 p.m. ET</p>

***Fiscal Year 2019 Neurofibromatosis Research Program (NFRP)***  
***Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Early Investigator Research Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> W81XWH-19-NFRP-EIRA</p>	<p>The investigator must:</p> <ul style="list-style-type: none"> <li>• Be involved in a postdoctoral training or medical residency program; and</li> <li>• Possess at least 1 and up to 4 years of continuous postdoctoral research experience by the Early Investigator Research Award application submission deadline; and</li> <li>• Possess a clinical doctoral degree (i.e., Ph.D., M.D./Ph.D., D.O./Ph.D.) or a clinical doctoral degree (i.e., M.D./D.O. or Ph.D. in a clinical discipline) from an accredited organization or program.</li> </ul>	<ul style="list-style-type: none"> <li>• Supports NF-focused research opportunities for individuals in the early stages of their careers.</li> <li>• Investigators must have a designated mentor who is an experienced NF researcher.</li> </ul>	<ul style="list-style-type: none"> <li>• The maximum period of performance is <b>2</b> years.</li> <li>• The maximum allowable funding for the entire period of performance is <b>\$200,000</b> in direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.</li> </ul>	<p><b>Pre-application (Letter of Intent):</b> May 23, 2019 5:00 p.m. ET</p> <p><b>Confidential Letters of Recommendation:</b> June 11, 2019 5:00 p.m. Eastern Time</p> <p><b>Application:</b> June 6, 2019 11:59 p.m. ET</p>